

# MULTI-STAKEHOLDER WORKSHOP

---

New modalities in cancer  
drug development

**31 March - 1 April 2025**

**Brussels, BE**

**Hybrid Workshop**



## EVENT OUTLINE

---

Diagnosis and treatment of cancer has seen a steep evolution of new treatment paradigms in the recent years. In this multi-stakeholder workshop organized by the Cancer Drug Development Forum, multidisciplinary experts will discuss key emerging treatment modalities – looking at these new developments from scientific, regulatory and practical perspectives. Novel modalities to be covered include: radiopharmaceuticals as a means to both diagnose and treat tumors; personalized vaccines as cancer immunotherapeutics; the next generation of targeted conjugates; and new approaches to tackle previously undruggable targets. In addition, cellular therapies like CAR-T cells, having become standard of care in several cancers, are still evolving, and we will cover lessons learned and the implications for new approaches on the horizon.

This multistakeholder workshop will give participants the opportunity to hear about the latest developments from hands-on experts in the field. The 1.5 day meeting consists of four plenary sessions. Panel discussions will enhance each session, always striving to involve the patient perspective, and the perspective of Regulatory Authorities. There will be time for discussion and networking, involving multiple stakeholders including industry, academics, regulatory agencies, HTAs, and, importantly, patient advocates.

## LEARNING OBJECTIVES

---

From this interactive workshop, participants will achieve the following outcomes:

- To understand the latest treatment paradigms in the diagnosis and treatment of cancer
- To learn about regulatory principles, including practical aspects which help regulating new modalities
- To look back at what can be learned from current cutting edge treatments already authorized, enabling a wider view of how to develop new paradigms in future

## PROGRAMME COMMITTEE

---

- Programme chair: Stefan Symeonides (CDDF, UK)
- Programme chair: Christian Schneider (CDDF, DE)
- Hemal Morjaria (Johnson & Johnson, UK)
- Sacha Wissink (MSD, NL)
- PA

## TARGET AUDIENCE

---

The target is a multidisciplinary audience of academia representatives, EU and US regulatory bodies (EMA, FDA, National Agencies), pharmaceutical Industry, HTAs and patient advocate.

## WORKSHOP VENUE

---

Brussels Marriott Hôtel Grand Place  
Rue August Orts 3-7, Brussels, 1000

## HYBRID WORKSHOP

---

The workshop will be held in Brussels. However, participation online via the Brella event platform will also be possible. Only approved participants will receive the link and log-in details to access the virtual platform.

## CONTACT

---

Cancer Drug Development Forum (CDDF)  
Email: [giorgia@cddf.org](mailto:giorgia@cddf.org), [info@cddf.org](mailto:info@cddf.org)  
Website: [www.cddf.org](http://www.cddf.org)  
Address: c/o BLSI Clos Chapelle-aux-Champs 30, 1200 Brussels, Belgium

# PROGRAMME

Day 1 : Monday, 31 March 2025

---

## SESSION 1: WHAT IS NEW IN ONCOLOGY

Session Chairs: Christian Schneider (CDDF, DE); Erik Briers (Europa Uomo, BE)

|               |                                                                                               |
|---------------|-----------------------------------------------------------------------------------------------|
| 12:00 - 12:45 | Lunch                                                                                         |
| 12:45 - 12:50 | Welcome note with polls<br>Programme chair                                                    |
| 12:50 - 13:00 | Session introduction<br>Christian Schneider (CDDF, DE); Erik Briers (Europa Uomo, BE)         |
| 13:00 - 13:15 | Bispecific and their variants; T cell engagers<br>Ulrike Philippar (Johnson & Johnson, BE)    |
| 13:15- 13:30  | New Opportunities in Undruggable Targets Using TPD<br>Ian Churcher (Janus Drug Discovery, UK) |
| 13:30 - 14:10 | Panel Discussion                                                                              |
| 14:10 - 14:40 | Coffee break                                                                                  |

## SESSION 2: RADIOPHARMACEUTICALS

Session Chairs: Hemal Morjaria (Johnson & Johnson, UK); Oliver Kiß (Helmholtz-Zentrum Dresden-Rossendorf, DE)

|               |                                                                                                        |
|---------------|--------------------------------------------------------------------------------------------------------|
| 14:40 - 14:45 | Session opening                                                                                        |
| 14:45 - 15:00 | Access and basic principles of radiopharmaceuticals<br>Viktor Grünwald (University Hospital Essen, DE) |

|               |                                                                                                                                                                                                                                                                             |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 15:00 - 15:15 | Advancements in Radiopharmaceutical and emerging guidance<br>Oliver Kiß (Helmholtz-Zentrum Dresden-Rossendorf, DE)                                                                                                                                                          |
| 15:15 - 15:30 | From Bench to Bedside: Innovations in Radionuclide Therapy for Solid Tumors- The latest breakthroughs in radionuclide/ radiopharmaceutical treatments<br>Christophe Deroose (UZ Leuven, BE)                                                                                 |
| 15:30 - 16:15 | Panel Discussion<br>Guest Panelists: <ul style="list-style-type: none"> <li>• Dirk Van Genechten (Vzw NET en MEN Kanker, BE)</li> <li>• Chuck Drake (Johnson &amp; Johnson, US)</li> <li>• Stephen Moran (Novartis, CH)</li> <li>• Erik Briers (Europa Uomo, BE)</li> </ul> |
| 16:15- 16:45  | Coffee Break                                                                                                                                                                                                                                                                |

## SESSION 3: PERSONALIZED VACCINES IN ONCOLOGY

Session Chairs: Sacha Wissink (MSD, NL); Samra Turajlic (Francis Crick Institute; the Royal Marsden, UK)

|               |                                                                                                                                                                                                     |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 16:45- 16:50  | Session opening                                                                                                                                                                                     |
| 16:50 - 17:05 | Short overview, including vector technology, types of antigens<br>Samra Turajlic (Francis Crick Institute; the Royal Marsden, UK)                                                                   |
| 17:05 - 17:20 | Individualized Neoantigen Therapy: The needle-to-needle process<br>Clemens Krepler (MSD, US)                                                                                                        |
| 17:20 - 17:35 | Personalised treatments from regulatory perspective<br>Olga Kholmanskikh (FAMHP, BE)                                                                                                                |
| 17:35 - 18:15 | Panel Discussion<br>Guest panelist: <ul style="list-style-type: none"> <li>• Carole Longson (Carole Longson Consultant, UK)</li> <li>• Helen White (PPI Collaborator, Oxford Cancer, UK)</li> </ul> |
| 18:30 - 19:30 | CDDF Leadership and Industry Panel Meeting (internal meeting)                                                                                                                                       |
| 19:30 - 22:00 | Offsite dinner (Aux Armes de Bruxelles)                                                                                                                                                             |

## Day 2 : Tuesday, 1 April 2025

### SESSION 4: CELLULAR THERAPIES

Session Chairs: Stefan Symeonides (CDDF, UK); Debbie Keatley (ICPV, UK)

|               |                                                                                                                                                                                                          |
|---------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 08:30 - 10:00 | CDDF Board of Directors meeting (internal meeting)                                                                                                                                                       |
| 10:15 - 10:20 | Session opening                                                                                                                                                                                          |
| 10:20 - 10:35 | Cellular therapies and GMOs: What is out there and pipeline<br>Vladimir Galvao (Vall d'Hebron Institute of Oncology, ES)                                                                                 |
| 10:35 - 10:50 | Delivery of them: Learnings from CAR T cells<br>Tobias Menne (Newcastle University, UK)                                                                                                                  |
| 10:50 - 11:05 | 15 years of ATMPs: EU regulatory framework<br>Caroline Pothet (EMA, NL)                                                                                                                                  |
| 11:05 - 11:45 | Panel Discussion<br>Guest Panelists: <ul style="list-style-type: none"> <li>• Deepu Madduri (Johnson &amp; Johnson, US)</li> <li>• Sahar van Waalwijk van Doorn-Khosrovani (CZ Insurance, NL)</li> </ul> |

### SESSION 5: DISCUSSION SESSION ON COMMON CHALLENGES

Session Chairs: Stefan Symeonides (CDDF, UK); Christian Schneider (CDDF, DE)

|               |                                                                                                                                                                                                                                                               |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11:45 - 12:15 | Wrap up panel discussion<br>Guest panelists: <ul style="list-style-type: none"> <li>• Carole Longson (Carole Longson Consulting, UK)</li> <li>• Caroline Pothet (EMA, NL)</li> <li>• Debbie Keatley (ICPV, UK)</li> <li>• Clemens Kepler (MSD, US)</li> </ul> |
| 12:15 - 12:25 | Farewell message                                                                                                                                                                                                                                              |
| 12:30 - 13:30 | Takeaway lunch and departure                                                                                                                                                                                                                                  |